Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?-Reference-Cited by-同舟云学术

Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?

Published:2023-12 Issue:12 Volume:34 Page:2051-2052
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Chen Jun-Zhang¹,Liang Bo²^ORCID

Affiliation:

1. Department of Paediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

2. Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nephrology,General Medicine

Reference4 articles.

1. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM);Perico;J Am Soc Nephrol.,2023

2. Clinical translation of mesenchymal stromal cell therapies in nephrology;Perico;J Am Soc Nephrol.,2018

3. Heterogeneous nature of renal lesions in type II diabetes;Gambara;J Am Soc Nephrol.,1993

4. Autologous adipose mesenchymal stem cell administration in arteriosclerosis and potential for anti-aging application: a retrospective cohort study;Ohta;Stem Cell Res Ther.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?;Journal of the American Society of Nephrology;2023-12